. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral
Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1
and GEMINI-2 Randomized Clinical Trials: Erratum. J Acquir Immune Defic Syndr 2020;84:e21.
PMID: 32530908